Cancer of Unknown Primary Site Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0089665 (Cancer of Unknown Primary Site)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03752333Trial of Pembrolizumab in Cancer of Unknown PrimaryTreatment